当前他汀使用时长与肌萎缩侧索硬化风险:挪威人群队列研究
该研究基于挪威大型人群健康调查与全国行政数据链接,纳入425,564名40-65岁参与者,随访平均16年,识别493例ALS。分析显示,当前他汀使用0-1年者ALS风险显著升高(HR 3.56),而长期使用5-17年者风险降低(HR 0.67),尤其在男性中明显。
要点
- 短期他汀使用与ALS风险升高相关,提示反向因果可能。
- 长期他汀使用(5-17年)与男性ALS风险降低相关。
- RAS-acting药物使用与ALS风险无明确关联。
核心结论
- 短期当前他汀使用与ALS风险升高相关,可能反映反向因果;长期使用与男性ALS风险降低相关。
研究设计与样本
- 基于挪威人群健康调查与全国行政数据链接的队列研究,纳入425,564名40-65岁参与者,平均随访16年。
主要发现
- 共识别493例ALS病例(44%女性)。
- 与无当前他汀使用相比,当前使用0-1年者ALS的HR为3.56(95%CI 2.58-4.90)。
- 当前使用1-5年者HR为0.85(95%CI 0.59-1.23),5-17年者HR为0.67(95%CI 0.45-1.00)。
- 男性中短期使用HR为4.03(95%CI 2.72-5.95),长期使用HR为0.47(95%CI 0.26-0.86)。
- RAS-acting药物短期或长期使用与ALS风险无明确关联。
临床怎么用
- 临床解读他汀与ALS关联时需考虑反向因果,短期使用风险升高可能源于 prediagnostic 阶段。
- 长期他汀使用与男性ALS风险降低的关联需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Although hypercholesterolemia may contribute to long-term amyotrophic lateral sclerosis (ALS) risk, it can also seem as a secondary effect during the early, prediagnostic phase of the disease. We aimed to investigate the relationship between short-term and long-term use of statins and subsequent ALS risk. METHODS: We designed a cohort study where information on cardiovascular risk factors among Norwegian participants in large population-based health surveys was linked to nationwide administrative data on subsequent statin use and ALS diagnosis. Duration of statin use was calculated based on cumulative defined daily doses and analyzed as time-varying exposure with 3 levels: 0-1 year (short-term), 1-5 years, and 5-17 years (long-term). In Cox regression models adjusted for sex, age, health survey participation, triglyceride and cholesterol levels, body mass index, smoking, diabetes, and hypertension, we calculated hazard ratios (HRs) for ALS according to time-varying statin exposure. In a negative control analysis, we examined whether exposure to renin-angiotensin system (RAS)-acting agents was associated with ALS risk. RESULTS: A total of 425,564 participants (54% women), aged 40-65 years in January 2005, were followed for a mean period of 16 years (SD 2.3) during which 493 ALS cases (44% women) were identified. Compared with no current statin use, the HR for ALS was 3.56 (95% CI 2.58-4.90) for those with 0-1 year, 0.85 (95% CI 0.59-1.23) for those with 1-5 years, and 0.67 (95% CI 0.45-1.00) for those with 5-17 years of current use. The associations between both short-term and long-term statin use and ALS risk were most evident in men, with HRs for ALS of 4.03 (95% CI 2.72-5.95) and 0.47 (95% CI 0.26-0.86), respectively. There was no clear association between either short-term or long-term use of RAS-acting agents and ALS risk. DISCUSSION: The strong association between short-term current statin use and increased ALS risk is consistent with reverse causality, where statin initiation in the prediagnostic phase may occur when lipid levels rise and individuals seek medical attention due to emerging ALS symptoms. Long-term statin use was associated with reduced risk of ALS in men.
引用
- Nakken O, Vaage AM, Stigum H, et al. Duration of Current Statin Use and Amyotrophic Lateral Sclerosis Risk: A Norwegian Population-Based Cohort Study. Neurology. 2025. PMID: 41026994. doi:10.1212/WNL.0000000000214221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。